# A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

> **NCT07386847** · — · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 3000 (estimated)

## Conditions studied

- Metastatic Urothelial Carcinoma
- Urothelial Cancer
- Urothelial Carcinoma
- Locally Advanced or Metastatic Urothelial Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07386847
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-30
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07386847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07386847, "A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07386847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*